TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioVersys AG ( (CH:BIOV) ) just unveiled an announcement.
BioVersys AG, in collaboration with GSK, has dosed the first patient in a Phase 2 clinical trial to evaluate the efficacy and safety of alpibectir-ethionamide (AlpE) combined with first-line TB drugs. This trial, supported by the European Union’s UNITE4TB initiative, aims to address drug-resistant tuberculosis, a significant global health threat, and represents a crucial step in developing new treatment regimens.
More about BioVersys AG
BioVersys AG is a clinical-stage biopharmaceutical company focused on developing novel antibacterial products to combat serious infections caused by multidrug-resistant bacteria. The company collaborates with partners like GSK and is involved in initiatives such as UNITE4TB to advance treatments for tuberculosis.
YTD Price Performance: -1.85%
Average Trading Volume: 9,349
For detailed information about BIOV stock, go to TipRanks’ Stock Analysis page.